Deciphera Pharmaceuticals (DCPH) Stock Price
Deciphera Pharmaceuticals Price
Over the last 4 years Deciphera Pharmaceuticals grew revenue by 59.9% annually, reaching 163.36 M USD. For Deciphera Pharmaceuticals, the net margin of -119.3% is up versus -766.0% a few years ago.
Deciphera Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Deciphera Pharmaceuticals business model & stock analysis
Frequently asked questions about Deciphera Pharmaceuticals
The business model of Deciphera Pharmaceuticals Inc revolves around developing and commercializing targeted therapeutics for the treatment of cancer. With a primary focus on kinase inhibitors, Deciphera Pharmaceuticals aims to address unmet medical needs and improve patient outcomes. The company prioritizes the discovery and development of small molecule drugs, leveraging its proprietary Kinase Switch Control Inhibitor Platform. By combining innovative science, strategic partnerships, and rigorous clinical research, Deciphera Pharmaceuticals aims to bring transformational therapies to patients living with cancer.
Deciphera Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
Deciphera Pharmaceuticals Inc faces competition from several players in the market. Some of its main competitors include Blueprint Medicines Corporation, Array BioPharma Inc, and Loxo Oncology Inc. These companies are also engaged in the research and development of innovative therapies and treatments in the pharmaceutical industry. However, Deciphera Pharmaceuticals distinguishes itself through its unique approach and expertise in developing highly targeted precision medicine solutions. With its strong pipeline and advancements in kinase inhibitor drugs, Deciphera Pharmaceuticals Inc aims to stand out as a leading player in the market.
Deciphera Pharmaceuticals Inc. is a renowned biopharmaceutical company, known for its innovative approach in developing kinase inhibitor therapies to improve the lives of patients. Founded in 2003 and headquartered in Waltham, Massachusetts, Deciphera has made significant advancements in precision medicine by targeting the underlying causes of cancer and other diseases. With a focus on kinase switch control inhibitors (KSCIs), the company strives to provide effective treatment options for patients with various types of cancers and other serious diseases. Deciphera's dedication to research and development has led to the discovery of multiple potential drug candidates, establishing them as a key player in the pharmaceutical industry.
Deciphera Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and gained regulatory approval for their lead kinase inhibitor, Qinlock® (ripretinib), to treat advanced gastrointestinal stromal tumors (GIST). Deciphera Pharmaceuticals also obtained accelerated approval from the U.S. FDA for Qinlock® as a fourth-line therapy for GIST patients. Furthermore, they received breakthrough therapy designation from the FDA for Qinlock® in the second-line GIST treatment setting. These milestones highlight Deciphera Pharmaceuticals' commitment to developing innovative treatments for rare cancers and their dedication to advancing patient care.
Deciphera Pharmaceuticals Inc is primarily present in the United States.
Deciphera Pharmaceuticals Inc represents a strong commitment to improving patients' lives through innovative oncology treatments. Guided by a patient-centric approach, the company focuses on personalized medicine that targets specific cancer signaling pathways. Deciphera Pharmaceuticals Inc believes in advancing precision oncology therapies to address unmet medical needs and strives to make a significant impact in the field of cancer research. With their dedicated team and cutting-edge research, Deciphera Pharmaceuticals Inc is devoted to developing transformative therapies that provide hope and enhance the quality of life for patients with cancer.
16 analysts currently rate the Deciphera Pharmaceuticals stock: 7 recommend buying, 9 holding and 0 selling. For 2026, analysts expect Deciphera Pharmaceuticals to generate revenue of 379.79 M USD and earnings per share of -0.58 USD.
Converted at the current exchange rate, the Deciphera Pharmaceuticals share trades at 22.92 EUR (25.59 USD).
The Deciphera Pharmaceuticals share (DCPH) is listed on 4 stock exchanges, including: NASDAQ (DCPH), Frankfurt (D05.F), München (D05.MU), Düsseldorf (D05.DU).
Deciphera Pharmaceuticals Inc. is a biopharmaceutical company that develops innovative drugs for the treatment of cancer. The company operates in three main areas: clinical development, research and development, and marketing. The clinical development division focuses on developing drugs for the treatment of cancer. The research and development division specializes in discovering new drugs for cancer treatment. The marketing division works closely with partners to market the company's medical innovations worldwide. The company's goal is to improve the lives of cancer patients and extend their survival through the development and marketing of effective drugs. Overall, Deciphera Pharmaceuticals is committed to improving the lives of cancer patients globally.
The expected revenue of Deciphera Pharmaceuticals is 379.79 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Deciphera Pharmaceuticals is -49.19 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Deciphera Pharmaceuticals is currently -44.22. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Deciphera Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Deciphera Pharmaceuticals is currently 5.73. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Deciphera Pharmaceuticals stock.
The Eulerpool Quality Score for Deciphera Pharmaceuticals is 4/10.
The ISIN of Deciphera Pharmaceuticals is US24344T1016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Deciphera Pharmaceuticals is A2H48H. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Deciphera Pharmaceuticals is DCPH. The ticker symbol is used to trade Deciphera Pharmaceuticals shares on the stock exchange.
Deciphera Pharmaceuticals stock
Deciphera Pharmaceuticals Peer Group
Deciphera Pharmaceuticals Ticker
Deciphera Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Deciphera Pharmaceuticals
Our stock analysis for Deciphera Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Deciphera Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.